XASX
SHL
Market cap6.88bUSD
Jun 18, Last price
19.84AUD
1D
-0.20%
1Q
-1.15%
Jan 2017
-7.29%
Name
Sonic Healthcare Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Sydney, Australia, in 1934, Sonic Healthcare Limited is a prominent international provider of extensive medical diagnostic services. The company caters to a wide array of clients, including individual medical practitioners, hospitals, community health organizations, and, by extension, their patients. Sonic Healthcare's core operations are divided into three main service categories: 1. Laboratory Medicine/Pathology: This segment offers a broad spectrum of diagnostic testing, encompassing biochemistry, cytopathology (cell analysis), genetic screening, haematology (blood analysis), histopathology (tissue examination), immunoserology (immune system testing), microbiology (infectious disease detection), molecular pathology, prenatal testing, and toxicology, alongside various supporting laboratory functions. 2. Radiology Services: The company provides advanced medical imaging, which includes magnetic resonance imaging (MRI), computed tomography (CT) scans, ultrasound, X-ray, mammography, nuclear medicine, PET CT scans, interventional procedures, and bone mineral densitometry for assessing bone density. 3. Primary Care Medical Services: Sonic Healthcare also delivers a range of general practice and community health solutions. These comprise general practitioner clinics, occupational health support, specialized clinics for skin cancer, after-hours GP services, IT solutions designed for general practices, and other community-based healthcare initiatives. With a substantial global presence, Sonic Healthcare Limited conducts its operations across Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and other international regions.
IPO date
Sep 25, 1934
Employees
41,000
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||